US OptionsDetailed Quotes
ANIX250117P5000
- 2.70
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open2.70Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV21.23%PremiumJan 17, 2025Expiry Date2.08Intrinsic Value100Multiplier-5DDays to Expiry0.62Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Anixa Biosciences Stock Discussion
Sign in to post a comment
$Fenbo Holdings (FEBO.US)$ $New Horizon Aircraft (HOVR.US)$ $Netflix (NFLX.US)$ $EON Resources (EONR.US)$ $Anixa Biosciences (ANIX.US)$ $One Stop Systems (OSS.US)$ $Cardio Diagnostics (CDIO.US)$ $Metagenomi Technologies, LLC (MGX.US)$ $ImmunoPrecise Antibodies (IPA.US)$ $DIREXION DAILY NFLX BULL 2X SHARES (NFXL.US)$ $Boqii (BQ.US)$ $New Era Helium (NEHC.US)$ $US Energy (USEG.US)$ $Asset Entities (ASST.US)$
📊⚡️📊
📊⚡️📊
7
4
$Anixa Biosciences (ANIX.US)$
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. ...
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. ...
2
$Anixa Biosciences (ANIX.US)$
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• Data continues positive trend as additional patients are enrolled in 3 cohorts
• Vaccine was safe and well tolerated by participants in all 3 cohorts
• Protocol defined immune responses were exhibited in over 70% of patients
• A Phase 2 study evaluating the vaccine in the n...
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
• Data continues positive trend as additional patients are enrolled in 3 cohorts
• Vaccine was safe and well tolerated by participants in all 3 cohorts
• Protocol defined immune responses were exhibited in over 70% of patients
• A Phase 2 study evaluating the vaccine in the n...
$Anixa Biosciences (ANIX.US)$ Reuters· just
Anixa Biosciences Inc - to Release Phase 1 Breast Cancer Vaccine Data on Nov 8
Anixa Biosciences Inc - to Release Phase 1 Breast Cancer Vaccine Data on Nov 8
$Anixa Biosciences (ANIX.US)$
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Anixa Biosciences (NASDAQ: ANIX) has announced its strategic plan for a Phase 2 study of its breast cancer vaccine. The trial will evaluate the vaccine's efficacy in combination with chemotherapy and Keytruda in a neoadjuvant setting. This approach allows for a broader patient range and a potentially faster path to approval. The therapeutic breast cancer market is projected to reach $89.67 bil...
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Anixa Biosciences (NASDAQ: ANIX) has announced its strategic plan for a Phase 2 study of its breast cancer vaccine. The trial will evaluate the vaccine's efficacy in combination with chemotherapy and Keytruda in a neoadjuvant setting. This approach allows for a broader patient range and a potentially faster path to approval. The therapeutic breast cancer market is projected to reach $89.67 bil...
$Anixa Biosciences (ANIX.US)$ no love for this one? approval from FDA but no movement, dam sad
Anixa Biosciences Announces FDA Approval of Individual Patient IND for Ovarian Cancer CAR-T Therapy.
Anixa Biosciences Inc. (NASDAQ: ANIX) recently announced a milestone in its collaborative efforts with Moffitt Cancer Center. The U.S. Food and Drug Administration (FDA) has granted approval for an individual patient Investigational New Drug Application (IND), allowing the administration of a second dose of its CAR-T therapy fo...
Anixa Biosciences Inc. (NASDAQ: ANIX) recently announced a milestone in its collaborative efforts with Moffitt Cancer Center. The U.S. Food and Drug Administration (FDA) has granted approval for an individual patient Investigational New Drug Application (IND), allowing the administration of a second dose of its CAR-T therapy fo...
$Anixa Biosciences (ANIX.US)$ sad no movement
4
No comment yet
Khan 7 : The above picture is the stock scanners or anyone other website. I want to learn it. This is very accurate.
David 889 : moomoo has these stocks on the pre-market Top Gainers list!
103648682 David 889 : where to get?
David 889 : You can find the pre-market gainers on Featured Lists in Market - US Stocks section on moomoo.